[1] McFadden DC,Freis BC,Wang F,et al.Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans[J].Eukaryot Cell,2007,6(8):1464-1473.
[2] Zaragoza O,Rodrigues ML,De JM,et al.The capsule of the fungal pathogen Cryptococcus neoformans[J].Adv Appl Microbiol,2009,68:133-216.
[3] Saha DC,Xess I,Zeng WY,et al.Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis[J].Med Mycol,2008,46(5):457-463.
[4] Fonseca FL,Frases S,Casadevall A,et al.Structural and functional properties of the Trichosporon asahii glucuronoxylomannan[J].Fungal Genet Biol,2009,46(6-7):496-505.
[5] McFadden DC,Freis BC,Wang F,et al.Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans[J].Eukaryot Cell,2007,6(8):1464-1473.
[6] Pietrella D,Lupo P,Fries B,et al.Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response[J].Cell Microbiol,2003,5 (8):513-522.
[7] Vecchiarelli A.Immunoregulation by capsular components of Cryptococcus neoformans[J].Med Mycol,2000,38 (6):407-417.
[8] Goldman DL,Lee SC,Casadevall A.Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody[J].Infect Immun,1995,63(9):3448-3453.
[9] Vecchiarelli A,Monari C.Microbial polysaccharide:new insights for treating autoimmune diseases[J].Front Biosci,2010,1 (2):256-267.
[10] Yauch LE,Lam JS,Levitz SM.Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan[J].PLoS Pathog,2006,2(11):120.
[11] Monari C,Pericolini E,Bistoni G,et al.Cryptococcns neoformans capsular glucuronoxylomannan induces expression of Fas ligand in macrophages[J].J Immunol,2005,174 (6):3461-3468.
[12] Vecchiarelli A,Pietrella D,Lupo P,et al.The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation[J]. J Leukocyte Biol,2003,74 (3):370-378.
[13] Monari C,Bistoni F,Vecchiarelli A.Glucuronoxylomannan exhibits potent immunosuppressive properties[J].FEMS Yeast Res,2006,6(4):537-542.
[14] Monad C,Bevilacqua S,Piccioni M,et al.A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production[J].J Immunol,2009,183(1):191-200.
[15] Maxson ME,Cook E,Casadevall A,et al.The volume and hydration of the Cryptococcus neoformans polysaccharide capsule [J].Fungal Genet Biol,2007,44(3):180-186.
[16] Rodrigues ML,Nakayasu ES,Oliveira DL,et al.Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence[J]. Eukaryot Cell,2008,7(1):58-67.
[17] 王高峰,孔庆涛,王雪连,等.新生隐球菌荚膜研究现状[J].中国真菌学杂志,2010,5(5):312-314.
[18] Oliveira DL,Nimrichter L,Miranda K,et al. Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan[J].Fungal Genet Biol,2009,46(12):956-963.
[19] Nimrichter L,Frases S,Cinelli LP,et al.Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations[J].Eukaryotic Cell,2007,6(8):1400-1410.
[20] Diane C,Mc F,Oscar Z,et al.Immunoreactivity of Cryptococcal antigen is not stable under prolonged incubations in human serum[J].J Clin Microbiol,2004,42(6):2786-2788.
[21] Bryan RA,Zaragoza O,Zhang T,et al.Radiological studies re-veal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans[J].Eukaryot Cell,2005,4 (2):465-475.
[22] Rodrigues ML,Alvarez M,Fonseca FL,et al.Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan[J].Eukaryot Cell,2008,7 (4):602-609.
[23] Karashima R,Yamakani Y,Yamagata E,et al.Increased release of glucuronoxylomannan antigen and induced pbenotypic changes in Trichosporon asahii by repeated passage in mice[J].Med Microbiol,2002,51(5):423-432.
[24] Fries BC,Goldman DL,Cherniak R,et al.Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and gluculonoxylomannan structure[J].Infect Immun,1999,67(11):6076-6083.
[25] Beenhouwer DO,Yoo EM,Lai CW,et al.Human immunoglobulin G2 (IgG2) and IgG4,but not IgG1 or IgG3,protect mice against Cryptococcus neoformans infection[J].Infect Immun,2007,75(3):1424-1435. |
